open access

Vol 60, No 5 (2009)
Original papers
Published online: 2009-10-30
Submitted: 2013-02-15
Get Citation

The influence of peptides from the angiotensin family on tyrosine kinase activity and cell viability in a human hormone-dependent prostate cancer line

Kamila Domińska, Agnieszka Wanda Piastowska, Elżbieta Rębas, Agnieszka Lachowicz-Ochędalska
Endokrynologia Polska 2009;60(5):363-369.

open access

Vol 60, No 5 (2009)
Original papers
Published online: 2009-10-30
Submitted: 2013-02-15

Abstract


Introduction: The results of many studies have reported that peptides from the angiotensin family are involved in the regulation of cell growth, proliferation, cell migration, apoptosis, inflammation, differentiation, and angiogenesis, which suggests that they might play an important role in carcinogenesis. The role of the renin–angiotensin system in supporting prostate cancer induction and progression has so far received little study.
Material and methods: The present study was to examine the influence of Ang II, Ang III, and Ang IV on a human hormone-dependent prostate cancer line (LNCaP). Using an isotopic method, we tested the effects of angiotensins on tyrosine kinase activity, and measured cell viability using an MTT Assay.
Results: The results showed that only Ang IV significantly reduced tyrosine kinase activity and cell viability in LNCaP cells. The process seemed to be mediated partly by AT2 and probably by another type of receptor with high affinity for Ang IV and low affinity for PD123319 and Losartan.
Conclusions: These findings suggest that components of the renin-angiotensin system, specifically angiotensin peptides and receptors (AT1, AT2) can modify prostate cancer cell viability.

Abstract


Introduction: The results of many studies have reported that peptides from the angiotensin family are involved in the regulation of cell growth, proliferation, cell migration, apoptosis, inflammation, differentiation, and angiogenesis, which suggests that they might play an important role in carcinogenesis. The role of the renin–angiotensin system in supporting prostate cancer induction and progression has so far received little study.
Material and methods: The present study was to examine the influence of Ang II, Ang III, and Ang IV on a human hormone-dependent prostate cancer line (LNCaP). Using an isotopic method, we tested the effects of angiotensins on tyrosine kinase activity, and measured cell viability using an MTT Assay.
Results: The results showed that only Ang IV significantly reduced tyrosine kinase activity and cell viability in LNCaP cells. The process seemed to be mediated partly by AT2 and probably by another type of receptor with high affinity for Ang IV and low affinity for PD123319 and Losartan.
Conclusions: These findings suggest that components of the renin-angiotensin system, specifically angiotensin peptides and receptors (AT1, AT2) can modify prostate cancer cell viability.
Get Citation

Keywords

hormone-dependent prostate cancer; LNCaP; cell viability; PTKs; losartan; PD123319

About this article
Title

The influence of peptides from the angiotensin family on tyrosine kinase activity and cell viability in a human hormone-dependent prostate cancer line

Journal

Endokrynologia Polska

Issue

Vol 60, No 5 (2009)

Pages

363-369

Published online

2009-10-30

Bibliographic record

Endokrynologia Polska 2009;60(5):363-369.

Keywords

hormone-dependent prostate cancer
LNCaP
cell viability
PTKs
losartan
PD123319

Authors

Kamila Domińska
Agnieszka Wanda Piastowska
Elżbieta Rębas
Agnieszka Lachowicz-Ochędalska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl